Every Form 4 that Aktis Oncology, Inc. (AKTS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AKTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTS filings page.
Aktis Oncology director Ken Herrmann exercised vested stock options and sold the resulting shares on July 20, 2026. He exercised options for 3,506 shares at $0.08 per share and 1,350 shares at $1.91 per share, acquiring 4,856 common shares. He then sold 4,856 common shares at a weighted average price of $24.5622 per share in transactions priced between $24.50 and $24.66.
Aktis Oncology, Inc. director Ken Herrmann reported a same-day option exercise and sale. He exercised 3,065 stock options at $0.0800 per share into 3,065 shares of common stock, then sold 3,065 shares at a weighted average price of $25.2067, with individual trades between $25.00 and $25.4950. The exercised options were fully vested, and 3,506 options from this award remained outstanding, expiring November 23, 2030.
Aktis Oncology, Inc. executive Shulamit Ron-Bigger, Chief Operating Officer, reported an exercise-and-sale transaction in company equity. On July 8, 2026, she exercised stock options to acquire 50,000 shares of common stock at an exercise price of $3.66 per share and on the same date sold 50,000 shares of common stock in multiple open-market transactions at weighted average prices around the high-$20s per share. After these transactions, she continued to hold 217,888 stock options expiring in 2032.
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026. He exercised stock options to acquire 50,000 shares at $4.95 per share, then sold 50,000 shares in multiple open-market sales at weighted average prices around the high-$20s range, leaving no Common Stock held directly and 221,218 stock options outstanding with a $4.95 exercise price expiring on June 30, 2034.
Aktis Oncology director Glenn Gormley received a grant of 37,866 stock options to buy common stock at an exercise price of $18.09 per share. The options expire on April 15, 2036. According to the vesting terms, one-third vests on April 15, 2027 and the remaining shares vest in equal annual installments thereafter, subject to his continuous service through each vesting date.
Aktis Oncology director and 10% owner Todd Foley reported indirect changes in ownership tied to the company’s initial public offering. Investment funds affiliated with MPM converted preferred stock into common stock and also bought additional shares.
On January 12, 2026, 2,272,727 Series Seed, 10,227,273 Series A and 2,727,273 Series B redeemable convertible preferred shares automatically converted into 597,391, 2,688,270 and 716,872 shares of common stock, respectively, at a 3.8044-for-1 ratio with no additional payment upon the IPO closing. The affiliated funds also purchased 232,870 common shares at $18 each, bringing their indirect common stock holdings to 4,235,403 shares.
The shares are held across MPM BioVentures 2018, L.P., MPM BioVentures 2018 (B), L.P. and MPM Asset Management Investors BV2018 LLC, and the reporting persons disclaim beneficial ownership beyond their pecuniary interest.
Aktis Oncology large shareholders affiliated with MPM BioVentures 2018 reported major equity changes tied to the company’s initial public offering. On January 12, 2026, entities in the group converted Series Seed, Series A and Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044-for-1 ratio, resulting in 1,314,262, 5,914,197 and 1,577,119 shares of common stock from each series, respectively. The group also reported purchasing an additional 1,112,777 common shares at $18 per share. Following these transactions, the reporting entities indirectly held a total of 10,260,064 Aktis Oncology common shares spread across several investment funds. The reporting persons state that they disclaim beneficial ownership except to the extent of their pecuniary interest.
Aktis Oncology insider funds reported major share conversions and a purchase tied to its initial public offering. On January 12, 2026, investment entities linked to MPM converted 5,000,000 Series Seed, 22,500,000 Series A and 6,000,000 Series B Redeemable Convertible Preferred Stock into common shares at a 3.8044‑for‑1 rate, issuing 1,314,262, 5,914,197 and 1,577,119 common shares, respectively.
These common shares are held across multiple MPM vehicles, including MPM Asset Management LLC, several MPM BioVentures funds, MPM Oncology funds and Oncology Impact Private Investment Fund 2, L.P. The MPM‑affiliated funds also purchased 1,112,777 shares of Aktis Oncology common stock at $18 per share, bringing their indirectly held common stock to 10,260,064 shares. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Aktis Oncology, Inc. director-affiliated investment funds advised by EcoR1 Capital, LLC reported a series of equity transactions in connection with the company’s initial public offering. On January 12, 2026, shares of Series A and Series B Redeemable Convertible Preferred Stock held by EcoR1-advised funds converted into Common Stock and Class A Common Stock on a 3.8044-for-1 basis immediately before the IPO closing for no additional consideration.
The filing also shows the EcoR1-advised funds purchased 2,077,779 and 144,443 shares of Common Stock at $18 per share. Each share of Class A Common Stock is convertible into one share of Common Stock at the holder’s election for no additional consideration, subject to a 4.99% beneficial ownership limitation. The securities are held by EcoR1 Capital Fund Qualified, L.P., EcoR1 Capital Fund, L.P., and EcoR1 Venture Opportunity Fund, L.P.; EcoR1 and Oleg Nodelman may be deemed to indirectly beneficially own them but disclaim beneficial ownership beyond their pecuniary interests.
Vida Ventures II, LLC and Vida Ventures II-A, LLC, both 10% owners of Aktis Oncology, Inc., reported multiple transactions dated 01/12/2026. Series A and Series B Redeemable Convertible Preferred Stock automatically converted into Common Stock on a 3.8044-for-1 basis immediately before the closing of Aktis Oncology’s initial public offering, with no additional consideration paid.
Following these conversions and open-market purchases, Vida Ventures II, LLC indirectly held 5,671,825 shares of Common Stock after acquiring 4,859,370 shares through conversion and buying 812,455 shares at $18 per share. Vida Ventures II-A, LLC indirectly held 157,387 shares of Common Stock after receiving 134,842 shares through conversion and purchasing 22,545 shares at $18 per share.
Aktis Oncology, Inc. director and 10% owner Kim Helen Susan reported indirect ownership changes tied to the company’s initial public offering. Investment entities Vida Ventures II, LLC and Vida Ventures II-A, LLC converted their Series A and Series B Redeemable Convertible Preferred Stock into Common Stock on a 3.8044-for-1 basis immediately before the IPO closing, with no additional cash paid. Following these conversions and additional purchases at $18 per share on the same date, Vida Ventures II, LLC held 5,671,825 shares of Common Stock and Vida Ventures II-A, LLC held 157,387 shares, over which various Vida Ventures entities and committee members, including the reporting person, may be deemed to share voting and investment power, subject to pecuniary-interest disclaimers.
Aktis Oncology, Inc. director Segal Lloyd Mitchell reported an automatic conversion of preferred stock into common shares tied to the company’s initial public offering. On 01/12/2026, Arvala, Inc., an entity for which Mitchell is president and sole stockholder, converted 50,000 shares of Series A Redeemable Convertible Preferred Stock and 24,687 shares of Series B Redeemable Convertible Preferred Stock into the issuer’s common stock on a 3.8044-for-1 basis without any cash payment. This conversion resulted in 19,631 shares of common stock, all held indirectly through Arvala, Inc., and reflects the automatic conversion that occurred immediately before the closing of the IPO.